Vital

When the medication isn't working

Tirzepatide Not Working: Dose, Storage, and Vial Checks

If tirzepatide is not working, look at the dose step, how long you have been on it, how the pens or vials were stored, and whether a compounded product matches its label. Then bring a clear record to your prescriber.

Last reviewed

The Vital angle

Vital saves each tirzepatide dose with the amount, strength, source type, site, and next dose, and it shows the dose history next to your weight trend from Apple Health. Reminders help you keep the weekly day, and a note on a dose can record a new vial lot or a missed click for your prescriber.

Tirzepatide not working is a common worry, partly because the trial headlines set high expectations. In SURMOUNT-1, people on the highest dose lost about a fifth of their body weight on average over 72 weeks. That average came from people who reached full dose and stayed on it for well over a year. If your experience looks different so far, there is usually a reason worth looking at.

This guide covers Zepbound®, Mounjaro®, and compounded tirzepatide. It does not replace your prescriber. Do not change, skip, or double a dose on your own.

How tirzepatide differs from semaglutide

Tirzepatide acts on two hormone receptors, GIP and GLP-1, where semaglutide acts on GLP-1 alone. It is still a once-weekly injection with a slow start. Its half-life is about five to six days, a little shorter than semaglutide's. Some people notice the effect is strongest in the first days after a dose and softer near the end of the week. That pattern is covered in food noise coming back on a GLP-1.

The 2.5 mg dose is a starting dose

The Zepbound label starts everyone at 2.5 mg once weekly for four weeks. It states that 2.5 mg is for treatment initiation and is not approved as a maintenance dose. After four weeks the dose goes to 5 mg, and any further increase comes in 2.5 mg steps, each after at least four weeks on the current dose. Maintenance doses are 5 mg, 10 mg, or 15 mg weekly, with 15 mg as the maximum.

In practice:

  • Weeks 1 to 4 at 2.5 mg are for tolerance, not results.
  • Reaching 10 mg takes at least 12 weeks, and 15 mg at least 20 weeks.
  • If side effects meant staying at a step longer, add that time.

Many people lose some weight at 2.5 mg, and many do not. Either is normal. See GLP-1 not working in the first month for what the early weeks usually look like, and dosing schedules for how the steps work.

Storage rules are different for each format

Tirzepatide comes in several formats, and each has its own room-temperature limit. The Zepbound label says:

  • Single-dose pens and vials: refrigerate at 36 °F to 46 °F (2 °C to 8 °C). If needed, keep unrefrigerated up to 86 °F (30 °C) for a total of 21 days, then discard.
  • KwikPen and multi-dose vials: discard after 30 days at room temperature, 30 days after first use, or after four weekly doses, whichever comes first, even if medicine remains.
  • All formats: do not freeze, and do not use the product if it was frozen. Keep it in the carton, away from light.

If a pen sat in a hot car, froze, or passed its room-temperature limit, ask your pharmacist before you use it. For multi-dose formats, write down the first-use date on the carton. More detail is in GLP-1 left out of the fridge and travel with GLP-1 medication.

Make sure each dose went in

A dose that did not fully deliver can look like a dose that did not work. Things to check:

  1. With a single-dose pen, did you hold it against the skin until the injection finished, as the instructions for use describe?
  2. With a KwikPen, did you prime it as instructed, dial the correct dose, and hold the button for the full count?
  3. With a vial and syringe, was the amount correct, and did any liquid leak at the site?
  4. Were any doses missed or late?

The label lets you take a missed dose within four days (96 hours). After four days, you skip it and take the next dose on your usual day. Two doses must be at least three days (72 hours) apart. Several missed weeks in a row can mean restarting at a lower step, which is your prescriber's decision. See missed GLP-1 dose, Zepbound pen not working, and Mounjaro KwikPen not working.

If you use compounded tirzepatide

Compounded tirzepatide is not reviewed by the FDA for safety, effectiveness, or quality before it is sold. On December 19, 2024, the FDA decided that the tirzepatide injection shortage was resolved. That limits when pharmacies can legally copy the approved drug, but people still get compounded tirzepatide from many sources, and the quality varies.

Checks that help:

  • Concentration. Read mg per mL on the vial label. Some compounded tirzepatide is much more concentrated than others, so the same number of syringe units can mean a very different dose.
  • Written conversion. Ask the pharmacy to write down how many units equal your dose. The FDA has received reports of dosing errors from patients who measured the wrong dose.
  • Ingredients. Ask the pharmacy what is in the vial besides tirzepatide. The FDA warns that illegal online versions can contain the wrong or harmful ingredients.
  • Pharmacy licence. Confirm the pharmacy is state-licensed. The FDA says products labeled "for research purposes" or "not for human consumption" are of unknown quality.
  • Cold chain. Do not use a vial that arrived warm.
  • Vial age. The FDA generally advises discarding a multi-dose vial 28 days after first use.

If a new vial from a new batch seems to act differently, record the lot number and tell your prescriber. Read compounded GLP-1 vial storage and peptide catalog source checks for more on sources.

Habits and other causes

Tirzepatide reduces hunger and slows stomach emptying, but intake still matters. Liquid calories, grazing, and portion drift can offset part of the effect. Low protein can increase muscle loss. Short sleep and high stress make appetite harder to manage.

Some medicines can cause weight gain, including some antidepressants, antipsychotics, steroids, and insulin. Hypothyroidism and perimenopause can slow weight loss. Your prescriber can check for these.

If you lost steadily and then stopped, read weight loss plateaus and GLP-1 stopped working before you decide something is wrong.

What to ask your prescriber

Bring a simple record of each dose and its date, your weight trend over at least eight weeks, side effects, and the product details (brand or compounded, lot number, concentration). Then ask:

  1. Am I at the dose you intended for me, or is there room to increase?
  2. Have I been on the current dose long enough to judge it?
  3. Could a medicine or another condition be part of this?
  4. If this dose is my maximum tolerated dose, what are the next options?

When to get care now

Get medical help right away for:

  • Severe, persistent stomach pain, sometimes spreading to your back, with or without vomiting.
  • Signs of a serious allergic reaction, such as swelling of the face, lips, or throat, or trouble breathing.
  • Vomiting or diarrhea that leads to signs of dehydration, such as very little urine or dizziness.
  • Pain in the upper right stomach, fever, or yellow skin or eyes.
  • A lump in the neck, trouble swallowing, or hoarseness that does not go away.
  • Low blood sugar symptoms if you also take insulin or a sulfonylurea.

Also tell your care team before any surgery or procedure that needs anesthesia or deep sedation.


Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. Vital is independent and not affiliated with these companies.

Free toolGLP-1 medication level chart

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Expecting results at 2.5 mg

    The Zepbound label says 2.5 mg is for treatment initiation and is not approved as a maintenance dose. Reaching 10 mg takes at least 12 weeks, so early months are not a fair test.

  • Room-temperature limits passed

    Single-dose pens and vials allow 21 days unrefrigerated up to 86 °F. KwikPens and multi-dose vials allow 30 days or four doses. Product kept past these limits or frozen should not be used without asking a pharmacist.

  • Unclear compounded concentration

    Compounded tirzepatide comes in many concentrations, so the same syringe units can be a very different dose. The FDA has received reports of dosing errors from patients who measured the wrong dose.

  • Several missed weeks

    A missed dose can only be taken within four days. Repeated gaps lower the drug level and can mean your prescriber restarts you at a lower step.

  • Weight-gaining medicines or untreated conditions

    Some antidepressants, antipsychotics, steroids, insulin, hypothyroidism, and perimenopause can slow weight loss. A prescriber review can find these.

Frequently asked questions

  • Common reasons are a low starting dose, not enough weeks at each step, missed or partial doses, storage problems, or a compounded product whose strength is unclear. Review each with your prescriber or pharmacist.

  • Some people notice less hunger in the first weeks. The dose rises in 2.5 mg steps every four weeks or more, so reaching 10 mg takes at least 12 weeks. Most weight loss in trials came over many months at full dose.

  • The label says 2.5 mg is a starting dose and is not approved for maintenance. Some people lose weight on it and some do not. Both are normal.

  • Single-dose pens and vials can stay unrefrigerated up to 86 °F for a total of 21 days. KwikPens and multi-dose vials can stay at room temperature for 30 days. Do not use any format that froze.

  • The FDA does not review compounded tirzepatide for quality, and concentrations vary between pharmacies. A new concentration or batch can change the dose you draw. Ask the pharmacy to confirm your units in writing.

  • Talk to your prescriber with your dose history and weight trend. They can check for other causes and discuss other treatment options. Do not add or change medicines on your own.

Sources

  1. Zepbound (tirzepatide) Prescribing Information · Eli Lilly and Company
  2. Zepbound Dosage Options, Schedules and Missed Doses · Eli Lilly and Company
  3. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine
  4. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration
  5. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize · U.S. Food and Drug Administration

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.